Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02730962 · ClinicalTrials.gov registry record · Phase 2

Interventional Bioremediation of Microbiota in Metabolic Syndrome

A Phase 2 study, sponsored by University of Minnesota.

Terminated
Registry status
Phase 2
Development phase
12
Enrollment target

NCT02730962: Clinical Trial Phase 2 study, sponsored by University of Minnesota.

NCT02730962 is a Phase 2 study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02730962, a Phase 2 study, was terminated before completion, sponsored by University of Minnesota.

TERMINATED
Registry status
Phase 2
Development phase
12 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether changing the microbial composition in the colon can improve metabolism of sugar in people who are on the verge of developing diabetes (pre-diabetics). Study participants will undergo a fecal microbiota transplantation (FMT) using material from lean donors, as well as a series of tests prior to and after the transplant. The investigators will examine any changes in fecal bacterial composition associated with FMT and determine if any observed changes have an influence on blood sugar metabolism.

Primary Outcome

Insulin sensitivity measured by standard euglycemic insulin clamp.

Interventions

  • OTHER Placebo
  • DRUG Vancomycin
  • PROCEDURE Fecal Microbiota Transplantation
  • DRUG Clindamycin
  • DRUG Neomycin

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2016-06
Est. Completion 2018-01
Phase Phase 2
University of Minnesota

966 total trials

Why NCT02730962 stopped before completion

NCT02730962 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).

The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.

NCT02730962 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02730962 about?

NCT02730962 is a clinical study titled "Interventional Bioremediation of Microbiota in Metabolic Syndrome". The purpose of this study is to determine whether changing the microbial composition in the colon can improve metabolism of sugar in people who are on the verge of developing diabetes (pre-diabetics). Study participants will undergo a fecal microbiota transplantation (FMT) using material from lean d...

What is the current status of trial NCT02730962?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2016-06. Estimated completion is 2018-01.

What interventions are being tested in trial NCT02730962?

The interventions under investigation include: Placebo (OTHER), Vancomycin (DRUG), Fecal Microbiota Transplantation (PROCEDURE), Clindamycin (DRUG), Neomycin (DRUG).

Who is sponsoring clinical trial NCT02730962?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02730962's enrollment target sits among peer trials

12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02730962, the US trial registry maintained by the National Library of Medicine. NCT02730962 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.